Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND AND PURPOSE: In our institution, rotational 3D-conformal radiation therapy (also called conformation therapy) has been applied since the late 1970s to conform the target volume of high-dose radiation to the cancerous tissue while minimizing radiation to the surrounding normal tissues. This technique has been used most commonly to treat prostate cancers in combination with hormonal therapy. The results of Stage B2/C prostate cancer treated with this method were analyzed. PATIENTS AND METHODS: Between 1987 and 1997, 33 cases of prostate cancer were definitively treated with this method: 9 Stage B2 tumors and 24 Stage C tumors. Of these 33 tumors, 3 were well differentiated, 18 were moderately differentiated, and 12 were poorly differentiated. The average patient age was 75.6 years. The median pretreatment PSA value was 23.8 ng/ml. The total radiation dose ranged from 60 Gy to 70 Gy (average: 63.5 Gy) with conventional fractionation. Hormone therapy was administered permanently; the primary hormonal agent was diethylstilbestrol phosphate. RESULTS: The overall survival rate after 5 years was 58.2% and that after 10 years was 29.6%. The biochemical relapse-free rate after 5 years was 87.0% and that after 10 years was still 87.0%. There were 4 cases of biochemical failure, but no cases of death from prostate cancer. Stage, differentiation, and pretreatment PSA value were not prognostic factors. One of the 2 cases with delayed complications was a case of RTOG Grade 3 gastrointestinal complication. CONCLUSIONS: Rotational 3D-conformal radiation therapy combined with hormone therapy might be promising for the treatment of prostate cancer.

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

PURPOSE: The purpose of the current study was to evaluate the difference in prognostic factors between stage IB and II uterine cervical carcinoma patients treated with postoperative radiation therapy. PATIENTS AND METHODS: Between May 1988 and May 1998, a total of 94 patients including 47 patients with stage IB and 47 patients with stage II uterine cervical carcinoma were treated with postoperative radiation therapy at Tokyo Metropolitan Komagome Hospital. All patients were treated with 10 MV X-rays using an anterior-posterior parallel opposed field which covered the whole pelvis. Fractionation was 2 Gy per day, five fractions per week, to a total dose of 50 Gy. RESULTS: The 5-year overall survival rates of stage IB and II were 89.4% and 79.3%, respectively. In multivariate analysis for all patients, lymph node status, histology, and surgical margin status were recognized as prognostic factors. Limited to stage IB patients, lymph node status was the only independent prognostic factor. However, for stage II patients, tumor histology was also an independent prognostic factor. CONCLUSIONS: The prognostic factors of stage IB and II were different. Tumor histology was only associated with stage II patients. These findings suggested that tumor histology might have played a different role as tumor stage progressed. However, further studies with large numbers of patients will be required to confirm these results.

PubMed

researchmap

Language：English  

CiNii Books

CiNii Research

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

PURPOSE: Through a retrospective study of intraoperative radiation therapy (IORT) in bile duct cancer, we hope to help clarify its clinical usefulness. METHODS AND MATERIALS: Between 1976 and 1996, IORT was carried out in 35 patients with bile duct cancer at the Tokyo Metropolitan Komagome Hospital. Of the 35 patients, resection proved to be curative in 15. Intraoperative irradiation of 15-30 Gy (average 20.1 Gy) was delivered by electron beam in the 5- to 19-MeV energy ranges. Postoperative external-beam radiation therapy (EBRT) was also delivered in 16 patients. The EBRT was fractionated to 2 Gy/day, in principle, and was delivered at 8.8-54 Gy (average 40.4 Gy) by 10-MV X-rays. RESULTS: The median survival in our patients was 19 months. The 1-year, 2-year, and 5-year survival rates were 57%, 43%, and 19%, respectively. Statistical analysis identified the following prognostic factors: performance status, curative surgical resection, lymph node metastasis, IORT dosage, and treatment period. Only 1 patient (3%) died within 30 days after surgery, and the incidence of late-onset complications was 21%. CONCLUSION: The combination of IORT and EBRT is useful for patients with bile duct cancer who undergo noncurative resection or who have lymph node metastasis.

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND: We set out to review treatment policy, survival rate and acute and late sequelae of histologically confirmed seminoma patients who underwent orchiectomy and radiation therapy. MATERIALS AND METHODS: Thirty patients with testicular seminoma were investigated. The follow-up ranged from 1-20 years, with a median of 8.6 years. There were 23 patients with Stage I, six with Stage IIA and one with Stage IIB of the disease. All patients were treated with orchiectomy followed by iliac and paraaortic irradiation (median dose: 3900cGy for Stage I and 4000 cGy for Stage II patients). Up to 1986 the median total dose was 40Gy, and this dose was administered to sixteen patients. After that, fourteen patients received a total dose of 32Gy. RESULTS: For patients with Stage I and Stage II, 5- year disease-free survival rate was 100%. Twenty-three patients experienced certain acute reactions or side effects and all became well after radiation therapy; however, almost no patients showed severe late complications. CONCLUSION: In our study, radical orchiectomy and postoperative irradiation of iliac and paraaortic lymphaticus give good results for patients with Stage I and II testicular seminoma.

PubMed

researchmap

Language：Japanese   Publisher：(NPO)日本緩和医療学会  

researchmap

Language：Japanese   Publisher：(NPO)日本緩和医療学会  

researchmap

Language：English   Publisher：(一社)日本癌治療学会  

researchmap

Language：Japanese   Publisher：(公社)日本医学放射線学会  

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

日本医科大学千葉北総病院において非転移性前立腺癌37例に対する内分泌療法併用三次元原体照射放射線療法の治療結果を検討した。PSA nadirは1例を除き0.2ng/ml未満に低下し、5年PSA非再発率は87.9%、5年癌特異的生存率は97.0%であった。Grade3以上の有害事象は1例も認めなかった。(著者抄録)

researchmap